All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2016-12-21T16:13:50.000Z

The FDA grants KEYTRUDA® (pembrolizumab) Priority Review for the possible treatment of cHL

Dec 21, 2016
Share:

Bookmark this article

Keytruda®, or pembrolizumab, is a PD-1 inhibitor which has recently been accepted for Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of classical Hodgkin Lymphoma (cHL) in refractory patients or those who have relapsed after three lines of therapy.

The review is based on the KEYNOTE-013 phase I trial (NCT01953692) and KEYNOTE-087 phase II trial (NCT02453594) which showed positive data at a 200mg dose every three weeks. Updated long-term data on KEYNOTE-013 was presented this December at ASH 2016 and showed a durable response with an ORR of 58% and CRR of 19%.

Pembrolizumab was also a topic of discussion during an educational session at ASH 2016, titled “Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin Lymphoma” presented by Craig Moskowitz, one of the principal investigators on the KEYNOTE-087 trial. 

The expected target action date is currently set to be March 15th 2017.

  1. Zinzani, P.L. et al. Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). Blood. 3 Dec. 2015. DOI: 126.23 (2015): 3986.
  2. Chen, R. et al. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087. J Immunother Cancer. 4 Nov. 2015 DOI: 10.1186/2051-1426-3-S2-P146.
  3. CureToday online. December 1st http://www.curetoday.com/articles/keytruda-granted-priority-review-for-hodgkin-lymphoma. [Accessed December 2016].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox